By targeting a known receptor called CD71, ABX1100 delivers siRNA therapy to muscle tissue, where it inhibits the production of the GYS1 enzyme, which is responsible for synthesizing glycogen.

Aro’s lead program, ABX1100, is being developed for Pompe disease, and a phase 1 trial was recently initiated. In Pompe disease, mutations in the enzyme responsible for glycogen metabolism ...

The ESMO congress always disseminates the latest results of cancer research, a vibrant gathering and sharing of the latest data, communicating the next promising steps in oncological scientific ...

The European Society for Medical Oncology (ESMO) 2024 meeting was a well-attended affair at the sprawling Fira Gran Via centre in Barcelona. Amongst the excited hustle and bustle of new data and ...

Here you will find news stories and blog posts about the research our scientists have presented at the congress over the years. ESMO Virtual Plenary 2022: Major trial shows targeted drug improves ...